Guerra Veronica A, Jabbour Elias J, Ravandi Farhad, Kantarjian Hagop, Short Nicholas J
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Ther Adv Hematol. 2019 May 19;10:2040620719849496. doi: 10.1177/2040620719849496. eCollection 2019.
Adult acute lymphoblastic leukemia (ALL) has a poor overall survival compared with pediatric ALL where cure rates are observed in more than 90% of patients. The recent development of novel monoclonal antibodies targeting CD20, CD19, and CD22 has changed the long-term outcome of this disease, both in the frontline setting (e.g. rituximab) and for patients with relapsed/refractory disease (e.g. inotuzumab ozogamicin and blinatumomab). The CD3-CD19 bispecific T-cell-engaging antibody blinatumomab is also the first drug approved in ALL for patients with persistent or recurrent measurable residual disease, providing a new treatment paradigm for these patients. Several new agents are also in development that use novel constructs or target alternative surface epitopes such as CD123, CD25, and CD38. Herein, we review the role of monoclonal antibodies in adult ALL and summarize the current and future approaches in ALL, including novel combination therapies and the possibility of early incorporation of these agents into treatment regimens.
与小儿急性淋巴细胞白血病（ALL）相比，成人急性淋巴细胞白血病的总体生存率较低，小儿ALL的治愈率超过90%。最近开发的针对CD20、CD19和CD22的新型单克隆抗体改变了这种疾病的长期预后，无论是在一线治疗中（如利妥昔单抗），还是对于复发/难治性疾病患者（如奥英妥珠单抗和贝林妥欧单抗）。CD3-CD19双特异性T细胞衔接抗体贝林妥欧单抗也是首个被批准用于治疗持续性或复发性可测量残留病患者的ALL药物，为这些患者提供了一种新的治疗模式。还有几种新药物也在研发中，它们使用新型构建体或靶向其他表面表位，如CD123、CD25和CD38。在此，我们综述单克隆抗体在成人ALL中的作用，并总结ALL当前和未来的治疗方法，包括新型联合疗法以及将这些药物早期纳入治疗方案的可能性。
